ArticleClinical ophthalmology (Auckland, N.Z.)2008
Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review.
Article in Clinical ophthalmology (Auckland, N.Z.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 58 citations in OpenAlex.
- Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects.Korean journal of ophthalmology : KJO · 2014Trial
- Nimodipine Nanoparticles: A Promising Approach for Glaucoma Management.Pharmaceutics · 2025Article
- The Investigation of Latanoprost's Effects on the Intraocular Pressure of Healthy Male guinea Pigs Under Light and Dark Regimes.Veterinary medicine and science · 2025Article
- Self-assembled latanoprost loaded soluplus nanomicelles as an ophthalmic drug delivery system for the management of glaucoma.Scientific reports · 2024Article
- Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys.Translational vision science & technology · 2024Article
- The role of conventional and unconventional adaptive routes in lowering of intraocular pressure: Theoretical model and simulation.Physics of fluids (Woodbury, N.Y. : 1994) · 2023Article
- In-vivo inhibition of latanoprost induced iridal hyperpigmentation in rabbits- An investigational study.Heliyon · 2022Article
- Aqueous Prostaglandin Eye Drop Formulations.Pharmaceutics · 2022Review
- Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma.Journal of drug assessment · 2021Article
- Article
- Effect of Prostaglandin Analogues on Central Corneal Thickness: 3-Year Follow-up Results.Korean journal of ophthalmology : KJO · 2020Article
- Eye lymphatic defects induced by bone morphogenetic protein 9 deficiency have no functional consequences on intraocular pressure.Scientific reports · 2020Article
- Role of 24-Hour Intraocular Pressure Monitoring in Glaucoma Management.Journal of ophthalmology · 2019Review
- Effects of Topical Latanoprost on Intraocular Pressure and Myopia Progression in Young Guinea Pigs.Investigative ophthalmology & visual science · 2018Article
- 24-h Efficacy of Glaucoma Treatment Options.Advances in therapy · 2016Review
- Management of glaucoma in pregnancy: risks or choices, a dilemma?International journal of ophthalmology · 2016Review
- Twenty-four-hour intraocular pressure related changes following adjuvant selective laser trabeculoplasty for normal tension glaucoma.Medicine · 2014Observational
- Study of long term structural and functional changes in medically controlled glaucoma.International journal of ophthalmology · 2014Article
- Prodrug strategies in ocular drug delivery.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2012Review
- Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latanoprost is a prostaglandin F2-alpha isopropyl ester prodrug which is rapidly hydrolyzed by esterases in the cornea to the biologically active latanoprost acid. When latanoprost is topically administered into the eye, the cornea seems to act like as a slow-release depot to the anterior segment. One hour after administration maximum concentration is found in the iris, followed by the anterior chamber and the ciliary body. Despite extensive research, controversy remains about the real mechanism of action of this drug. Immunohistochemical data have shown that the intraocular pressure (IOP) reduction with topical prostaglandin F2-alpha is associated with a reduction of collagens within the uveoscleral outflow pathway. Evidence from several experimental and clinical studies suggests that latanoprost is a valuable addition first-line treatment alternatives for glaucoma, ocular hypertension and even angle-closure glaucoma. Strong points are its efficacy, which is demonstrated to be higher than that of brimonidine, dorzolamide and timolol with fewer systemic adverse effects; a convenient administration schedule; and the IOP-controlling pattern, which is relatively flat compared with timolol and dorzolamide, and enables better control in glaucoma progression, since large fluctuations may be associated with the risk of developing glaucoma in untreated ocular hypertensive subjects.
Indexed as
Identifiers
19668444PMC2699817W2027345384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.